Results 71 to 80 of about 33,833,464 (200)
Molecular Oncology, 2021 Dysfunctions in post‐transcriptional control are observed in cancer and chronic inflammatory diseases. Here, we employed a kinome inhibitor library (n = 378) in a reporter system selective for 3′‐untranslated region–AU‐rich elements (ARE).
Qamraa H. Al‐Qahtani +10 more
doaj +1 more source
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Targeting polo-like kinase 1 in acute myeloid leukemia [PDF]
Therapeutic Advances in Hematology, 2015 Polo-like kinase 1 (Plk1) plays a number of important roles in the passage of cells through mitosis. It is expressed at high levels in a variety of malignancies, including acute myeloid leukemia (AML). Inhibition of Plk1 results in cell cycle arrest and apoptosis, and has anti-tumor effects in pre-clinical models.
openaire +2 more sources
Entwicklung und Etablierung von induzierbaren RNAi-Systemen zur Regulierung der Expression von Polo-like Kinase 1 (Plk1) in vitro und in vivo [PDF]
, 2007 RNA-Interferenz (RNAi) erlangte eine herausragende Bedeutung zum Studium der Genfunktion, nachdem auch in Säugersystemen gezeigt wurde, daß durch Applikation von 21 nt langen siRNAs (small interfering RNAs) eine Sequenz-spezifische Degradierung der mRNA ...
Kappel, Sven
core
Molecules, 2019 Members of the polo-like kinase (Plk) family of serine/threonine protein kinases play crucial roles in cell cycle regulation and proliferation. Of the five Plks (Plk1–5), Plk1 is recognized as an anticancer drug target.
Xue Zhi Zhao +3 more
doaj +1 more source
Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1
Nature Communications, 2020 The BRCA2 tumour suppressor protein is known to play an important role in homologous recombination. Here the authors reveal how the phosphorylation of BRCA2 by Polo-like kinase 1 (PLK1) contributes to the regulation of mitosis.
Åsa Ehlén +12 more
doaj +1 more source
Nature Communications, 2021 Tavernier et al. decipher the mechanism by which the intrinsically disordered protein Bora, phosphorylated by Cyclin-Cdk, potentiates AURKA activity towards Polo-like kinase 1.
N. Tavernier +18 more
doaj +1 more source
Immunology, EarlyView.Human plasmacytoid dendritic cell‐based vaccines efficiently migrate from blood to lymph nodes and prime naive T cells in humanised mice. Irradiation‐induced CD62L shedding, mediated by p38 MAP kinase and ADAM17, is involved in the regulation of PDC migration to secondary lymphoid organs in this model.
Estelle Leplus +11 more
wiley +1 more source
Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer
Summary: Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations.
Justin Stebbing (181883) +1 more
core +5 more sources
Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis [PDF]
, 2012 Sphingosine kinases (SK) catalyze the phosphorylation of proapoptotic sphingosine to the prosurvival factor sphingosine 1-phosphate (S1P), thereby promoting oncogenic processes.
Zangemeister-Wittke, Uwe +15 more
core +2 more sources